XBiotech Inc. (NASDAQ:XBIT) Shares Sold by Empowered Funds LLC

Empowered Funds LLC reduced its position in XBiotech Inc. (NASDAQ:XBIT) by 9.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,551 shares of the biopharmaceutical company’s stock after selling 6,586 shares during the period. Empowered Funds LLC’s holdings in XBiotech were worth $484,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its position in shares of XBiotech by 1.6% in the first quarter. Vanguard Group Inc. now owns 895,315 shares of the biopharmaceutical company’s stock worth $7,279,000 after acquiring an additional 13,804 shares in the last quarter. Rhumbline Advisers increased its holdings in XBiotech by 2,568.5% in the 2nd quarter. Rhumbline Advisers now owns 20,094 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 19,341 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of XBiotech by 102.9% during the second quarter. Bank of New York Mellon Corp now owns 98,314 shares of the biopharmaceutical company’s stock worth $505,000 after purchasing an additional 49,863 shares in the last quarter. Finally, American Century Companies Inc. purchased a new stake in shares of XBiotech in the second quarter worth about $393,000. Hedge funds and other institutional investors own 55.70% of the company’s stock.

XBiotech Stock Performance

NASDAQ:XBIT opened at $6.83 on Monday. XBiotech Inc. has a one year low of $3.54 and a one year high of $9.96. The business’s 50-day simple moving average is $7.22 and its 200 day simple moving average is $6.88. The stock has a market cap of $208.18 million, a price-to-earnings ratio of -6.32 and a beta of 1.42.

XBiotech Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.